{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:17:34Z","timestamp":1787015854597,"version":"build-2736575974"},"reference-count":5,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Dystrophic epidermolysis bullosa (DEB) is a rare, inherited blistering skin disease with limited treatment options. Beremagene geperpavec (B\u2010VEC) is a herpes simplex virus type 1\u2010based topical gene therapy that is approved by the Food and Drug Administration (FDA) for the treatment of DEB at a fixed weekly dose. While B\u2010VEC has shown significant promise in treating DEB, few studies have examined off\u2010label use of B\u2010VEC at higher dose volumes. We describe the successful off\u2010label use of a temporarily increased B\u2010VEC dose in a patient with recessive DEB (RDEB) with extensive wounds following an episode of acute urticaria, highlighting the potential utility of higher dose B\u2010VEC in managing patients with extensive wound burden.<\/jats:p>","DOI":"10.1111\/pde.70065","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:00:42Z","timestamp":1759230042000},"page":"222-223","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Off\u2010Label Use of Double\u2010Dose Beremagene Geperpavec (B\u2010\n                    <scp>VEC<\/scp>\n                    ) in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: A Promising Clinical Case"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9046-0961","authenticated-orcid":false,"given":"Melissa M.","family":"Yamada","sequence":"first","affiliation":[{"name":"Washington University in St. Louis School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-7220","authenticated-orcid":false,"given":"Liza H.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine Washington University  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_2_1_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010020\u20100210\u20100"},{"key":"e_1_2_1_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0945\u2010053x(98)00007\u20109"},{"key":"e_1_2_1_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206663"},{"key":"e_1_2_1_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001737\u2010y"},{"key":"e_1_2_1_5_6_1","unstructured":"Krystal Biotech Inc \u201cVyjuvek (beremagene geperpavec\u2010svdt) [Package Insert]. U.S. Food and Drug Administration Website \u201daccessed May 16 2025 https:\/\/www.fda.gov\/media\/168350\/download?attachment."}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.70065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:29:42Z","timestamp":1769736582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.70065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/pde.70065"],"URL":"https:\/\/doi.org\/10.1111\/pde.70065","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2025-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}